VPRO Viropro Inc (CE)

VIROPRO (Pink Sheets: VPRO). At the coming stockholders meeting, the Company will seek approval to change its name.

Management believes the “viro” prefix no longer matches the nature of its business and a new name has been found however, unveiling of the name will take place at the meeting.

At said meeting, Company will also be seeking approval to increase authorized capital from 1 billion to 1.5 billion shares. The acquisition of Alpha Biologics Sdn. Bhd. announced February 22nd requires the issuance of 525,000,000 shares thus nearing the current authorized capital and more shares will need to be issued shortly to allow other acquisitions and fundings.

Company will be filing over the next few days its Preliminary Proxy Statement. This will be a Special Stockholders Meeting and to allow for proper dissemination of the Proxy Circular, date of meeting has been rescheduled to July 28.

About Viropro, Inc.:

Viropro, Inc. conducts operations through its subsidiaries Viropro International Inc., Biologics Process Development, Inc. and Alpha Biologics Sdn. Bhd. Viropro specializes in the transfer of its technologies for industrial production of biopharmaceutical therapeutic proteins for the treatment of various diseases including cancer, diabetes, hepatitis and multiple sclerosis. The Company’s principal objective is to provide its high-yield manufacturing process technology to biopharmaceutical companies in global markets with unmet medical and/or market needs. (www.viropro.com)

Viropro Inc. Safe Harbor Statement

Except for any purely historic statements contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933, as amended, and section 21E of the Exchange Act of 1934, as amended, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, and goals, assumptions of future events or performances are not statements of purely historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words such as "expects", "anticipates", "estimates", "believes", or words of similar import or statements indicating certain actions that "may", "could", or "might" occur. All forward-looking statements included in this press release are based upon information available to Viropro as of the date of this press release, and Viropro assumes no obligation to update any forward-looking statements. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties. These risks include, without limitation, the Company's ability to market its products and services in a competitive environment as well as other factors.

Viropro (CE) (USOTC:VPRO)
Historical Stock Chart
From Jun 2024 to Jul 2024

Viropro (CE) (USOTC:VPRO)
Historical Stock Chart
From Jul 2023 to Jul 2024